Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Sales Director
claire@zenopa.com
+44 1494 818025

Testimonials
Zenopa was extremely effective during my search for a new sales role. I was very pleased with the types of job role put forward and the consistent number of opportunities that my account manager conti...
Nina, 2013

Lilly announces results of phase III solanezumab study

9 October 2012 10:16 in Pharmaceutical Company Product News


Lilly has reported positive detailed results of the phase III trial into the efficacy of solanezumab for the treatment of Alzheimer's disease.

The double-blind, placebo-controlled Expedition investigation, which was carried out among patients with mild-to-moderate cases of the condition, revealed individuals administered with the compound demonstrated a slowing of cognitive decline.

Findings represented a 42 percent reduction in deterioration among patients at the endpoint of the 18-month study, while the difference in the functional worsening of the symptoms was not statistically different.

The announcement of the results comes after a presentation using analyses of the Expedition study data conducted by the Alzheimer's Disease Co-operative investigation at the annual meeting of the American Neurological Association.

Rachelle Doody, professor of Neurology and the Effie Marie Cain chair in Alzheimer's Disease Research at the Baylor College of Medicine, said: "These results represent an important step for the medical, academic and scientific communities in understanding brain amyloid as a target of Alzheimer's disease therapies."ADNFCR-8000103-ID-801465600-ADNFCR

Other news stories from 09/10/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd